Valeant Pharmaceuticals built a business model of acquiring smaller drug companies, gutting their R&D departments, and dramatically raising prices on existing drugs (many of which were under patent or life-saving), which created short-term earnings growth but was fundamentally a win-lose model that eventually collapsed.

causalpending

Speaker

Monish Pabrai

Evidence Quote

“Valiant would acquire smaller drug companies it would gut their R&D departments basically almost wipe them out and they would look at the portfolio of the all drugs that the company was selling and they would increase the hell out of the prices on those drugs”

Source

Mohnish Pabrai's Most Iconic Lecture Ever (Must Watch)— Investor Center
Created: 8/11/2026, 7:06:50 AM

Your notes

Loading notes...